<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246908</url>
  </required_header>
  <id_info>
    <org_study_id>CX157-201</org_study_id>
    <nct_id>NCT01246908</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression</brief_title>
  <acronym>CX157-201</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CeNeRx BioPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CeNeRx BioPharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if CX157 is effective and safe in patients with
      treatment of treatment resistant depression over six weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to examine the efficacy of CX157 Modified Release
      Tablet, 125 mg administered twice per day (BID) as compared to placebo in subjects with
      Treatment Resistant Depression (TRD). Secondary objectives are to evaluate the safety and
      tolerability of CX157 Modified Release Tablet, 125 mg BID in TRD subjects and characterize
      steady-state pharmacokinetic profile and explore pharmacodynamic relationships.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Over six weeks of study treatment</time_frame>
    <description>The MADRS will be administered by a trained rater at the study site and assess symptoms of depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of illness (CGI-S);</measure>
    <time_frame>Over six weeks of treatment with study drug.</time_frame>
    <description>To measure severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Improvement (CGI-I)</measure>
    <time_frame>Over six weeks of treatment</time_frame>
    <description>To measure overall improvment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression Rating Scale (HADS)</measure>
    <time_frame>over six weeks of treatment</time_frame>
    <description>To measure symptoms of depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>CX157 (TriRima)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered twice per day for six weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX157 (TriRima)</intervention_name>
    <description>One tablet administered twice per day (total daily dose of 250 mg) for six weeks.</description>
    <arm_group_label>CX157 (TriRima)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 20 to 65 years of age

          2. Able to read, understand and converse in English and provide written, dated informed
             consent

          3. Diagnosed with Major Depressive Disorder (MDD)and Treatment Resistant Depression(TRD)

          4. Females on acceptable method of contraception

        Exclusion Criteria:

          1. Major depressive episode greater than five years

          2. A history of a Substance Use Disorder with the exception of nicotine dependence in the
             past 12 months

          3. Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-traumatic Stress Disorder
             (PTSD

          4. A history of schizophrenia or schizoaffective disorders

          5. A history of anorexia nervosa, bulimia nervosa, or eating disorder not otherwise
             specified, within the past five years

          6. A history of Antisocial Personality Disorder or Borderline Personality Disorder

          7. Recent suicidal behavior and is at risk of such behavior during the course of the
             study

          8. Electroconvulsive therapy (ECT) within the past five years

          9. Transcranial Magnetic Stimulation (TMS) for the treatment of the current episode of
             depression

         10. Vagus Nerve Stimulation (VNS) at any time

         11. Any psychoactive drugs within one to four weeks prior to the randomization visit
             depending on the type of drug

         12. Significant abnormality on the screening physical examination

         13. Significant cardiac abnormalities such as uncontrolled hypertension, recent myocardial
             infarction, Congestive heart failure (CHF), Angina pectoris

         14. A history within the past two years of significant head trauma, surgical procedure
             involving the brain,degenerative central nervous system disorder (e.g., Alzheimer's or
             Parkinson's Disease), epilepsy, mental retardation

         15. A history of hypothyroidism and has been on a stable dosage of thyroid replacement
             medication for less than six months

         16. A history of hyperthyroidism which was treated (medically or surgically) less than six
             months prior to screening

         17. Participation in an investigational study in the past one month

         18. A positive screening urine test for drugs of abuse

         19. Female subject who is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Yeo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summitt Research Network - Oregon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ram Shrivastava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastside Comprehensive Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelo Sambunaris, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Institute of Medicine and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bijan Bastani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthCoast Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Stedman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stedman Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Weisler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richard H. Weisler, M.D. and Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Joyce, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neuroscience Solutions, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fares Arguello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerie Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neurosciences Solutions, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arif Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irving Kolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kolin Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jelena Kunovac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excell Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Steiert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summit Research Network (Seattle) LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorena Wallhauser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Patient Priority Clinical Sites, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Bari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prakash Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Escondido</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Downing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FutureSearch Trials of Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario Hidalgo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida College of Medicine Psychiatry Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alec Bodkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Pet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AccelRx Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beal Essink, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Center for Clinical Investigations, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Segal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Segal Institute of Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Simon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northbrooke Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charmaine Semeniuk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Prater, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gulfcoast Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Woyshville, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Star Medical Research LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Shapira, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carman Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Molpus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neuroscience Solutions, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Segal Institute of Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine Psychiatry Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolin Research Group</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Institute of Medicine and Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Shapira, MD, Ph.D</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccelRx Research</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Comprehensive Medical Center</name>
      <address>
        <city>NYC</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard H. Weisler, M.D. and Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthCoast Clinical Trials, Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Medical Research, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summitt Research Network (Oregon)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Introspect of Buxmont, Ltd</name>
      <address>
        <city>Colmar</city>
        <state>Pennsylvania</state>
        <zip>18915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neurosciences Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Seattle) LLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northbrooke Research Center</name>
      <address>
        <city>Deer Brown</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>July 8, 2012</last_update_submitted>
  <last_update_submitted_qc>July 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

